patients underwent valve replacement using the Bjork-Shiley tilting disc prosthesis. For the group as a whole hospital mortality was 13-3 per cent and was lowest in those undergoing isolated mitral or aortic valve replacement (5 3 and 9.4%, respectively). Available for follow-up were 209 patients of whom 123 were maintained on dipyridamoleand96on warfarin. Thromboembolic complications were significantly (P < 0.01) commoner in the dipyridamole (28 of 123, 22%) than warfarin (6 of 86, 7%) treated group. In the dipyridamole treated group the incidence of thromboembolic complications was similar whichever valve was replaced and thromboembolic complications were responsible for 14 ofthe 28 late deaths. In the warfarin treated group thromboembolic complications only occurred in patients with a mitral prosthesis. Anticoagulation is indicated for all patients with this prosthesis wherever inserted.
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Although valve replacement with biological and mechanical prostheses has been in clinical use for many years (Starr and Edwards, 1961) , the search for the ideal prosthesis has been pursued enthusiastically because of the high failure and complication rates from earlier forms of metal, plastic, and biological prostheses (Braunwald and Detmer, 1968) . Such a prosthesis would combine durability and non-thrombogenicity as well as interfering minimally with cardiac function. With increasing experience of valve replacement operative mortality has fallen, but systemic thromboembolism has remained the major cause of late mortality and morbidity despite careful anticoagulant control. The most frequent site of thrombus formation is upon the prosthesis itself (Arrigoni et al., 1973) , secondary to platelet deposition on the struts and base-plate, and on exposed metal or cloth-covered sewing rings. With no cage, small struts, a low profile sewing ring, and a tilting disc instead of a central occluder, the Bjork-Shiley valve seemed to meet the criteria for an ideal prosthesis. Gradients across the valve are small (Bjork et al., 1971) , there is a large orifice to tissue diameter permitting a more laminar central flow, and there is a low incidence of thromboembolism in patients on anticoagulants (Bjork, 1969) . Our own investigations show that when the Bjork-Shiley mitral prosthesis is assessed 'Present address: Mayo Clinic, Rochester, Minnesota, USA Received for publication 24 June 1977 in terms of left ventricular filling rate and filling time (determined echocardiographically), it is less obstructive than either the Starr-Edwards prosthesis or the Hancock xenograft (Sutton et al., 1977) . Because of these features we have used this prosthesis at the Brompton Hospital.
Although long-term anticoagulants have been strongly recommended in all patients with artificial valves (Gadboys et al., 1967) , comparable results have been obtained using dipyridamole and salicylates combined (Harker and Slichter, 1970 (Sutton et al., 1977 (Weiss, 1974) . In arterial thrombogenesis, the deposition of platelets and their subsequent aggregation at sites of blood vessel injury and on prosthetic valves plays a more important role (Arrigoni et al., 1973) and fibrin formation occurs late.
Thus one way of reducing the incidence of arterial thromboembolism would be to select for clinical use agents that change platelet properties by reducing their adhesiveness, thus inhibiting platelet agggregation and deposition. Dipyridamole has been shown to reduce platelet adhesiveness and aggregation (Emmons et al., 1965) and to inhibit thrombus formation in injured arterial tissue (Didisheim, 1968) . It has also been shown to reduce deposition of thrombus in indwelling arterial cannulae and extracorporeal shunts (Harker and Slichter, 1970; Cucuiana et al., 1971) . In conjunction with warfarin (Sullivan et al., 1971) or acetylsalicylic acid (Harker and Slichter, 1970; Dale et al., 1975) dipyridamole has been shown to reduce the incidence of thromboembolism in patients undergoing prosthetic valve replacement. It was our hope that to the haemodynamic advantages of the Bj6rk-Shiley prosthesis could be added the practical realisation of the theoretical advantages of dipyridamole, while the high incidence of severe haemorrhagic complications of long-term anticoagulants could be reduced.
Our results in 209 patients followed up for a mean period of approximately 2 years show a high incidence of thromboembolic complications in the dipyridamole treated group significantly different (P<0.01) from the incidence in warfarin treated patients. This is in agreement with Bjork and Henze's recently published series (1975) which suggested that the frequency of thromboembolism in patients treated with dipyridamole was the same as in patients on no treatment at all. We freely admit that, as with much clinical experience, our study falls short of ideal requirements for a statistically acceptable investigation. Inparticular,allocation to the dipyridamole or warfarin groups was not randomised and the patients were not matched. Indeed the majority of the dipyridamole treated patients were from the Middle East, and racial and climatic differences might be held to be the cause of the increased incidence of thromboembolic complications in this group. There is, however, no evidence that arterial thromboembolism is more common in Middle Eastern countries and our experience is similar to that of Bjork and Henze in Sweden. While a prospective randomised trial would be a better method of investigating the feasibility of using dipyridamole alone, our own experience has been so chastening that we no longer feel justified in withholding anticoagulant treatment from any patient with a Bj6rk-Shiley prosthesis and feel that such an experience is worth reporting in case others might be tempted to initiate a similar method of management.
Thromboembolism was most frequent in patients undergoing mitral valve replacement, and a high proportion (8 out of 13) of these presented with mitral valve obstruction. At operation or necropsy, thrombus appeared to arise from the struts on the atrial side, growing through the valve so as to obstruct the left ventricular inflow tract and render the tilting Delrin disc immobile. Similar valve encapsulation has been described by Bjork and Henze (1973) . Obstruction of a (mitral) prosthesis occurred in only one patient who was well anticoagulated with warfarin. Of the 8 patients presenting with mitral valve obstruction, 3 had major systemic emboli during the month before admission to hospital, but had not sought medical attention until they presented with severe pulmonary oedema. On clinical examination the cardinal diagnostic feature was that both prosthetic opening and closing sounds were indistinct or absent. Echocardiographic assessment of left ventricular filling showed it to be characteristically slow (Sutton et al., 1977) . Thrombectomy was successfully carried out in one patient. The other 7 died before or during reoperation.
Three patients presented with aortic prosthetic valve malfunction caused by thrombotic obstruction. In all deterioration was very rapid within 24 hours of admission, all presented with severe left ventricular failure and had absent valve sounds. All died, one during reoperation for thrombectomy.
The incidence of thromboembolic complications in the group of patients treated with warfarin was low, and was of the same order as that reported by Bjork et al. (1973) and Bonchek and Starr (1975a) 
